2019
Chemotherapy Costs and 21-Gene Recurrence Score Genomic Testing Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005 to 2011.
Dinan MA, Wilson LE, Reed SD. Chemotherapy Costs and 21-Gene Recurrence Score Genomic Testing Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005 to 2011. Journal Of The National Comprehensive Cancer Network 2019, 17: 245-254. PMID: 30865923, DOI: 10.6004/jnccn.2018.7097.Peer-Reviewed Original ResearchConceptsLow-risk diseaseHigh-risk patientsHigh-risk diseaseRS testingMedicare beneficiariesPrimary analysisEstrogen receptor-positive breast cancerReceptor-positive breast cancerLower chemotherapy useIntermediate-risk diseaseIntermediate-risk patientsRetrospective cohort studyGenomic testingSEER-Medicare dataChemotherapy useCohort studyMultivariable analysisBreast cancerChemotherapy costsLow overall useMAIN OUTCOMEMedicare populationPatientsHigher overall costsDisease
2016
Chemotherapy costs associated with receipt of the adoption of oncotype DX in early-stage breast cancer within the SEER-Medicare population.
Dinan M, Mi X, Reed S, Lyman G, Curtis L. Chemotherapy costs associated with receipt of the adoption of oncotype DX in early-stage breast cancer within the SEER-Medicare population. Journal Of Clinical Oncology 2016, 34: 32-32. DOI: 10.1200/jco.2016.34.7_suppl.32.Peer-Reviewed Original ResearchHigh-risk diseaseOncotype DXRisk diseaseChemotherapy costsODX testingBreast cancerAdjuvant chemotherapyRisk womenPatient outcomesEnd Results-Medicare dataEarly-stage breast cancerER-positive breast cancerReal-world clinical practiceIntermediate-risk womenSEER-Medicare populationLow-risk diseaseHigh-risk womenPositive breast cancerWorld clinical practiceActual patient outcomesTotal Medicare paymentsNCCN guidelinesOverall cohortMultivariable analysisPathologic features